ACM
CRBP icon

Aquatic Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Aquatic Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,555
Closed -$101K – 1316
2024
Q4 		$101K Buy
+8,555
New +$143K ﹤0.01% 1063

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aquatic Capital Management's CRBP Position: Q1 2025 in Review

Aquatic Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 8,555 shares — an estimated $101K sold.

Aquatic Capital Management first reported a position in CRBP in Q4 2024 and held it in 1 quarter. The position peaked at $101K in Q4 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Aquatic Capital Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Aquatic Capital Management sold 8,555 Corbus Pharmaceuticals shares in Q1 2025, an estimated $101K.
  • Aquatic Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Aquatic Capital Management's Corbus Pharmaceuticals position peaked at $101K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Aquatic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.